News
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high estimate of $65.00, and a low estimate of $54.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.16%.
Stocktwits on MSN14h
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The DipShares of Bristol Myers Squibb (BMY) fell more than 4% after the closing bell on Tuesday after the biopharma company reported ...
Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...
Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...
The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...
The stock's rise snapped a four-day losing streak.
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...
Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.
Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...
In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...
Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...
Jefferies analyst Akash Tewari lowered the firm’s price target on Bristol Myers (BMY) to $68 from $70 and keeps a Buy rating on the shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback